Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Open Forum
Vioxx case highlights class action difficulties
A decade of litigation over MSD's Vioxx may prompt reform around using class actions to prosecute pharmaceutical product liability cases, writes Norton Rose Fulbright partner Toby Biddle.
Pipeline Monitor
New drugs in diabetes, cancer and serious infection
Actavis, Sanofi, Otsuka, Novartis, Amgen and BI have all enjoyed success with new drugs on the global stage in the week just passed.
Working Life
Will your job survive 2015? Our annual forecast
Which pharma industry sectors are hiring and which are firing in 2015? This cut from Pharma in Focus' latest White Paper gives you the lowdown.
Approvals Action
Long wait over for blood cancer treatment
After securing US approval in 2009, blood cancer treatment Folotyn has arrvied in Australia; a new dose of Copaxone has also been registered but not by current sponsor bioCSL.
Analysis
Trust deficit holding back Aussie pharma
Why, when it expects continuing increases in sales and profits, does Aussie pharma remain stuck in an ongoing cycle of negative sentiment?